Misplaced Pages

Sebetralstat

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound

Pharmaceutical compound
Sebetralstat
Clinical data
Other namesKVD-900
ATC code
Identifiers
IUPAC name
  • N--3-(methoxymethyl)-1-phenyl]methyl]pyrazole-4-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC26H26FN5O4
Molar mass491.523 g·mol
3D model (JSmol)
SMILES
  • COCC1=NN(C=C1C(=O)NCC2=NC=CC(=C2F)OC)CC3=CC=C(C=C3)CN4C=CC=CC4=O
InChI
  • InChI=1S/C26H26FN5O4/c1-35-17-22-20(26(34)29-13-21-25(27)23(36-2)10-11-28-21)16-32(30-22)15-19-8-6-18(7-9-19)14-31-12-4-3-5-24(31)33/h3-12,16H,13-15,17H2,1-2H3,(H,29,34)
  • Key:KGMPDQIYDKKXRD-UHFFFAOYSA-N

Sebetralstat is an investigational new drug that is being evaluated for the treatment of hereditary angioedema. It is a plasma kallikrein inhibitor.

References

  1. "Sebetralstat - KalVista Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
  2. Davie RL, Edwards HJ, Evans DM, Hodgson ST, Stocks MJ, Smith AJ, et al. (October 2022). "Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema". Journal of Medicinal Chemistry. 65 (20): 13629–13644. doi:10.1021/acs.jmedchem.2c00921. PMC 9620001. PMID 36251573.
Other hematological agents (B06)
Enzymes (B06AA)
Drugs used in hereditary
angioedema (B06AC)
Drugs used in sickle cell disease
and beta thalassemia (B06AX)
Others


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: